Abstract
Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1215-1216 |
| Number of pages | 2 |
| Journal | Mayo Clinic Proceedings |
| Volume | 80 |
| Issue number | 9 |
| State | Published - 2005 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. / Long, Jennifer K.; Choueiri, Toni K.; Hall, Geraldine S.; Avery, Robin; Sekeres, Mikkael A.
In: Mayo Clinic Proceedings, Vol. 80, No. 9, 2005, p. 1215-1216.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
AU - Long, Jennifer K.
AU - Choueiri, Toni K.
AU - Hall, Geraldine S.
AU - Avery, Robin
AU - Sekeres, Mikkael A.
PY - 2005
Y1 - 2005
N2 - Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.
AB - Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.
UR - http://www.scopus.com/inward/record.url?scp=24144466852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24144466852&partnerID=8YFLogxK
M3 - Article
VL - 80
SP - 1215
EP - 1216
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 9
ER -